
Nashua native, cancer survivor Tejeda, 23, running Boston Marathon for Mass. General Hospital
WHEN Nathanael 'Smiley' Tejeda got to know Dave Jurewicz, he realized that they have a lot in common.
They're around the same age. Tejeda, a Nashua native, is 23, and Jurewicz recently turned 20.
Jurewicz studies at Springfield College, where Tejeda got his undergraduate degree in exercise science.
They also have the same oncologist.
Jurewicz recently finished his treatment at Massachusetts General Hospital (MGH) for Hodgkin lymphoma, the same kind of cancer that Tejeda had.
Tejeda was diagnosed at MGH with stage 2 Hodgkin lymphoma in 2019 at age 17. Now cancer-free, Tejeda is partnered with Jurewicz through MGH for the April 21st Boston Marathon.
Tejeda is running Boston — it will be his first-ever marathon — as part of MGH's marathon team. Jurewicz will cheer Tejeda on with the other MGH runners' patient partners near Mile 20 in Newton, Mass., which comes just before Heartbreak Hill.
'I think, for me, it was really cool to just hang out with him and kind of show him, hey, man, life after treatment is not the end,' Tejeda said. 'You can honestly go on and continue to live your life and be the person you want to be. There's no holding back from what you are.'
Tejeda graduated from Springfield College last year. The Nashua South graduate is now working on his master's degree in exercise physiology with a focus on cancer research at the University of North Carolina.
With fewer than two weeks until the Boston Marathon, Tejeda has raised more than $11,000 for MGH on his GivenGain webpage.
Tejeda, who got the nickname 'Smiley' from one of his Pee Wee football teammates because of his upbeat attitude, was first diagnosed with Hodgkin lymphoma at MGH, where he also received his treatment.
Then in his senior year at South, Tejeda learned he had cancer the day after he reached the quarterfinals in the 195-pound weight class at the wrestling NHIAA Meet of Champions.
A few days before the meet, Tejeda discovered a golf-ball sized lump on his neck.
'I was kind of in shock,' Tejeda said. 'I didn't really fully understand at the time the severity of it all but knew that it was a big deal, and my family was very impacted by the whole situation.'
Tejeda, who also played football and baseball at South, didn't let cancer affect his signature 'Smiley' demeanor.
Purple Panthers baseball coach James Gaj still remembers how Tejeda told him about having to miss the season that spring.
'He sent me a text message,' Gaj said, 'and it said, 'Coach, I just want to let you know some of the good and some the bad — the bad news is I'm not going to be playing baseball because I was diagnosed with cancer. The good news is I caught it early.' His exact words were, 'I'm Gucci (good) — not to worry about it. I've never met anybody that had cancer and tell me that they're Gucci.'
Tejeda, a defensive end/offensive guard in football and third baseman/outfielder in baseball at South, never liked running. He has always been more of a weightlifter.
But being a patient partner for Eva Melanson, who ran the Boston Marathon on MGH's team in 2019, inspired him to do the same with the hospital that helped him beat cancer.
'I've said it a few times before to my family and my friends — this really is that full-circle moment of having been on the other side,' Tejeda said, 'and now I get to be on the flip side of this whole entire experience and really finish it off in the right way.'
Tejeda started his marathon training late last year and at one point was running between 30 and 40 miles per week. He ran his first half-marathon last April.
'Hopefully this won't be my last marathon,' Tejeda said. 'Hopefully this is just the beginning of a new chapter in my life.'
Scott Knight, who was Tejeda's football coach at South, wasn't surprised when he learned Tejeda was running the marathon in an effort to help others.
When Tejeda was going through his cancer treatment, he met with Make-A-Wish. For his Make-A-Wish options, he could have met a childhood hero or gone on a nice trip, Knight noted.
Instead, Tejeda had Make-A-Wish upgrade the South weight room.
'This is 'Smiley' to a T,' Knight said. 'He could have done anything ... but he chose to do something that would benefit others.'
That outlook led Tejeda to pursue his studies at UNC.
Tejeda knew he wanted to major in exercise science when he got to Springfield College. Because of his own experience, Tejeda realized while at Springfield that he wanted to work with cancer survivors and current cancer patients, using exercise to improve their quality of life.
Tejeda was drawn to North Carolina in part because of the school's exercise oncology research laboratory.
'He cares more about helping others than himself,' Gaj said of Tejeda. 'He's one of the most selfless people I've ever met in my life.'
ahall@unionleader.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
3 hours ago
- Associated Press
Record $50.4 million raised for charitable causes at 2025 Boston Marathon presented by Bank of America
Hundreds of organizations benefit as part of the Bank of America Boston Marathon Official Charity Program BOSTON, June 4, 2025 /PRNewswire/ -- The Boston Athletic Association (B.A.A.) announced today the total funds raised through the 2025 Boston Marathon presented by Bank of America reached a record $50.4 million -- surpassing last year's single-year record of $45.7 million. This year's $50.4 million total combines funds raised through the 176 non-profit organizations in the Bank of America Boston Marathon Official Charity Program, as well as other donations and fundraising from race participants. Total charitable fundraising since the official charity program's inception in 1989 now stands at over $600 million. 'Every year, participants and community members raise the bar and elevate the fundraising impact for meaningful causes throughout the community,' said Nicole Juri, Director of Development for the B.A.A. 'Their uplifting effect extends well beyond the 26.2-mile racecourse of the Boston Marathon. Athletes take pride in adding meaning to every step of their marathon journey, and together set new records in 2025.' Bank of America amplified fundraising runner stories through the My Marathoner campaign, showcasing the perseverance and determination of athletes who are part of the Bank of America Boston Marathon Official Charity Program. 'The power of the Boston Marathon is evidenced by its positive impact on hundreds of organizations and the causes they support, and the hundreds of thousands of people who benefit from the good work they do every day,' said David Tyrie, President, Marketing, Digital and Specialized Consumer Client Solutions at Bank of America. 'The fundraising total shows anything is possible when athletes from around the world, volunteers, local businesses, supporters and many more unite in the spirit of determination, selflessness and giving.' The Bank of America Boston Marathon Official Charity Program comprises nearly 10% of the Boston Marathon field size, with selected organizations utilizing their entries to recruit athletes who pledge to raise funds for their cause. A full list of organizations who were part of the 129th Boston Marathon presented by Bank of America can be found at Charity Program on the B.A.A. website. To further support participants' fundraising efforts, Boston Marathon Giving Day took place on March 20 – just over one month out from race day – where incentives were offered throughout the day. A single-day record $1.87 million was raised through this year's Boston Marathon Giving Day. In addition, 2018 Boston Marathon champion Des Linden led a run to build momentum and encouragement for fundraising runners and Bank of America employees. The B.A.A. had its own team as part of the official charity program, raising funds to support the organization's mission of promoting a healthy lifestyle through sports, especially running. The B.A.A. Gives Back Marathon Team raised more than $384,000 for the B.A.A.'s year-round youth and community programing, which includes more than a dozen events geared toward supporting runners at all points on their running journey. In addition, the inaugural B.A.A. Climate Crew team raised $83,000 geared towards the Boston Marathon's ongoing sustainability initiatives. Details on how to apply to be part of the Bank of America Boston Marathon Official Charity Program for 2026 can be found on the B.A.A. website. About the Boston Athletic Association (B.A.A.) Established in 1887, the Boston Athletic Association is a non-profit organization with a mission of promoting a healthy lifestyle through sports, especially running. The B.A.A. manages the Boston Marathon, and supports comprehensive charity, youth, and year-round programming. The economic impact of the 2024 Boston Marathon presented by Bank of America produced $509 million in state and local economic activity. The 129th Boston Marathon took place on Monday, April 21, 2025, while the 130th Boston Marathon presented by Bank of America will be held on Monday, April 20, 2026. The Boston Marathon is part of the Abbott World Marathon Majors, along with international marathons in Tokyo, London, Sydney, Berlin, Chicago, and New York City. For more information on the B.A.A., please visit the B.A.A. website. Reporters may contact: Chris Lotsbom Director of Race Communications & Media [email protected] Andy Aldridge, Bank of America Phone: 1.980.387.0514 [email protected] View original content to download multimedia: SOURCE Bank of America Corporation
Yahoo
6 hours ago
- Yahoo
EC approves Takeda ADC plus chemo for stage IIb Hodgkin's lymphoma
The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the chemotherapy regimen for adults with newly diagnosed Stage IIb Hodgkin's lymphoma (HL) with risk factors/III/IV. The chemotherapy regimen comprises etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD). This decision follows the Committee for Medicinal Products for Human Use's (CHMP) positive opinion in April 2025. The EC's approval is based on the Phase III HD21 trial outcomes, which showed that the Adcetris-based regimen, referred to as BrECADD, met its co-primary efficacy and safety endpoints. BrECADD demonstrated superior safety as evaluated by treatment-related morbidity (TRMB) and non-inferior progression-free survival compared to the escalated doses of standard of care treatment, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (eBEACOPP) in Europe. The HD21 study, conducted by the German Hodgkin Study Group (GHSG), was an open-label, multi-country, randomised trial assessing BrECADD's efficacy, feasibility, safety and tolerability. Adcetris, which leverages Pfizer's technology, has been previously approved in the European Union (EU) for six different indications in adults. Pfizer, along with Takeda, equally funds the co-development expenses for the ADC, except in Japan, where the latter manages the costs independently. Adcetris has received US Food and Drug Administration (FDA) approval for eight indications and was initially granted conditional marketing authorisation by the EC in October 2012. The conditions of this authorisation were fulfilled by May 2022. Takeda global oncology business unit president Teresa Bitetti stated: 'Today's approval represents a significant advancement for patients with Hodgkin lymphoma in the EU. "This approval reinforces the role of Adcetris as a backbone in the treatment of specific lymphomas, offering healthcare professionals greater flexibility to tailor treatment plans according to individual patient needs. We're proud to contribute another impactful option for those diagnosed with this challenging disease.' "EC approves Takeda ADC plus chemo for stage IIb Hodgkin's lymphoma" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Abby Lee Miller Sues Cedars-Sinai Hospital, Claims Doctors Left Catheter in Her Body
Abby Lee Miller's accusing a prominent Los Angeles-area hospital of malpractice ... claiming the doctors who performed surgery on her left a foreign object in her body. The "Dance Moms" star is suing Cedars-Sinai Marina Hospital and two doctors in relation to a 2020 surgery she got on her spine. While the surgery appeared to have been successful, Abby says she began suffering from abdominal pain and discomfort ... distress she says she shared with multiple medical professionals, including the two doctors who performed her surgery. Miller claims her complaints were waved away and largely ignored ... until she says one of her doctors finally performed a CT scan. According to Abby, the CT scan revealed a "retained catheter" she says was left inside her body after the surgery. She's suing for medical negligence, professional negligence, medical battery and more ... and asking for at least $1.4 million. ALM's been in a number of doctors' offices over the past few years because of her battle with Burkitt lymphoma, a rare type of non-Hodgkin lymphoma. The disease has affected her mobility, and she now uses a wheelchair in order to get around. A spokesperson for Cedars-Sinai tells TMZ ... "Cedars-Sinai cannot comment on pending legal matters. Also, due to federal and state privacy laws, Cedars-Sinai cannot discuss any patient's medical treatment." The spokesperson continues ... "However, the care and safety of our patients, staff and visitors are always Cedars-Sinai's top priorities. We are dedicated to ensuring that we meet the highest standards of care for all those we serve."